Optimal induction and post-remission therapy for AML in first remission.

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn , Issue , 2009, Pages 396-405

  Rowe, Jacob M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN;

ACUTE DISEASE; ADULT; AGE; AGED; BONE MARROW TRANSPLANTATION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LIVING DONOR; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; STATISTICS; SURVIVAL RATE;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; CYTARABINE; DAUNORUBICIN; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LIVING DONORS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SURVIVAL RATE; YOUNG ADULT;

EID: 77949449142     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2009.1.396     Document Type: Review

References (41)